Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of CN128 tablets in transfusion-dependent thalassemia with severe iron overload
CTR20220915Phase 2Completed
- Sponsor
- Hangzhou Zede Pharmaceutical Technology
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Tiralos in Thalassaemia and iron overload, sponsored by Hangzhou Zede Pharmaceutical Technology. Primary endpoints: Adverse events, Height, weight, and physical examination and 4 more. Started Jun 2022; status: completed.
02
Drugs
Tiralos
03
Conditions
Thalassaemiairon overload
Beyond the preview
Go deeper on CTR20220915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220915.